Conversation with The Cancer Letter NYU’s Caplan: Right to Try laws are meaningless, empty hot air, unethical, and utterly ineffective March 23, 2018Vol.44 No.12By Matthew Bin Han Ong
Right to Try edges closer to becoming federal lawLibertarians rejoice, but can it solve compassionate use problems? March 23, 2018Vol.44 No.12By Matthew Bin Han Ong
Trials & Tribulations Rare Cancers, Common Need March 16, 2018Vol.44 No.11By Sandip Patel, Young Kwang Chae and Razelle Kurzrock
Conversation with The Cancer LetterFree Porter: I can’t tell you how the Trump administration gets its budget numbers March 16, 2018Vol.44 No.11By Paul Goldberg
Conversation with The Cancer Letter Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable March 16, 2018Vol.44 No.11By Matthew Bin Han Ong
Do patients know best?Industry, NCI committing dollars to studying patient-reported outcomes March 16, 2018Vol.44 No.11By Matthew Bin Han Ong
Conversation with The Cancer LetterFree BMS’s Farajallah: Opdivo is the only PD-1 inhibitor approved for four-week dosing March 09, 2018Vol.44 No.10By Matthew Bin Han Ong
FreeGuest Editorial Beyond #MeToo:Sexual Harassment in Biomedicine March 09, 2018Vol.44 No.10By Kelly McBride Folkers
Free Beyond morphology:FDA mulls acute lymphoblastic leukemia drug based on elimination of “minimal residual disease” March 09, 2018Vol.44 No.10By Paul Goldberg
FreeTrials & Tribulations A phase III trial seeks to determine whether diet and exercise can cure breast cancer March 02, 2018Vol.44 No.09By Jennifer A. Ligibel
